Belgian Biotech gets a €40M Boost to Keep up in the CAR-T RaceBelgian biotech Celyad has raised substantial funding on Euronext Paris and the NASDAQ to support its CAR-T cell therapy, which can be applied to both solid and blood tumors. CYAD-01, its most advanced drug candidate, is currently in Phase I trials. The funding could help Celyad keep up with other CAR-T developers.

Even Old Brains Can Make New Neurons, Study FindsIn research published today in the journal Cell Stem Cell, scientists at Columbia University Vagelos College of Physicians and Surgeons present the most definitive evidence to date that the human brain makes new neurons throughout life.

Breakthrough in understanding of how red blood cells developBy taking a deep dive into the molecular underpinnings of Diamond-Blackfan anemia, scientists have made a new discovery about what drives the development of mature red blood cells from the earliest form of blood cells, called hematopoietic (blood-forming) stem cells.

Gilead to build its EU CAR-T manufacturing facility at Amsterdam airportSpeed is of the essence when it comes to manufacturing CAR T drugs—personalized treatments in which immune cells are engineered to recognize and destroy patients’ cancers. With that in mind, Gilead will locate a new European manufacturing site for its CAR-T therapy Yescarta at an airport in the Netherlands.

Leukaemia: protective role of Y chromosone gene discoveredScientists have discovered the first leukaemia protective gene that is specific to the male-only Y chromosome. Researchers at the Wellcome Sanger Institute and the University of Cambridge found that this Y-chromosome gene protects against the development of Acute Myeloid Leukaemia (AML) and other cancers.